{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Rodrigues-Krause J"],"pubmed_abstract":["l-Arginine supplementation is a potential therapy for treating cardiovascular and metabolic diseases. However, the use of distinct l-arginine sources, intervened populations, and treatment regimens may have yielded confusion about their efficacy. This research constitutes a systematic review and meta-analysis summarizing the effects of l-arginine supplementation compared to placebo in individuals with cardiovascular disease (CVD), obesity, or diabetes. Eligibility criteria included randomized clinical trials and interventions based on oral supplementation of l-arginine with a minimum duration of three days; comparison groups consisted of individuals with the same disease condition receiving an oral placebo substance. The primary outcome was flow-mediated dilation, and secondary outcomes we"],"journal":["Nutrients"],"pagination":["E15"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6357192"],"repository":["biostudies-literature"],"pubmed_title":["Association of l-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis."],"pmcid":["PMC6357192"],"pubmed_authors":["Krause M","Rodrigues-Krause J","Rocha IMGD","Umpierre D","Fayh APT"],"additional_accession":[]},"is_claimable":false,"name":"Association of l-Arginine Supplementation with Markers of Endothelial Function in Patients with Cardiovascular or Metabolic Disorders: A Systematic Review and Meta-Analysis.","description":"l-Arginine supplementation is a potential therapy for treating cardiovascular and metabolic diseases. However, the use of distinct l-arginine sources, intervened populations, and treatment regimens may have yielded confusion about their efficacy. This research constitutes a systematic review and meta-analysis summarizing the effects of l-arginine supplementation compared to placebo in individuals with cardiovascular disease (CVD), obesity, or diabetes. Eligibility criteria included randomized clinical trials and interventions based on oral supplementation of l-arginine with a minimum duration of three days; comparison groups consisted of individuals with the same disease condition receiving an oral placebo substance. The primary outcome was flow-mediated dilation, and secondary outcomes we","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Dec","modification":"2025-05-31T22:54:56.871Z","creation":"2025-05-31T22:54:56.871Z"},"accession":"S-EPMC6357192","cross_references":{"pubmed":["30577559"],"doi":["10.3390/nu11010015"]}}